Extended indication Treatment of type 2 diabetes mellitus
Therapeutic value No estimate possible yet
Registration phase Registration application pending

Product

Active substance Insulin efsitora alfa
Domain Metabolism and Endocrinology
Reason of inclusion New medicine (specialité)
Main indication Diabetes
Extended indication Treatment of type 2 diabetes mellitus
Manufacturer Eli Lilly
Mechanism of action Insulin preparation
Route of administration Subcutaneous
Therapeutical formulation Injection
Budgetting framework Extramural (GVS)

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
ATMP No
Submission date August 2025
Expected Registration September 2026
Orphan drug No
Registration phase Registration application pending

Therapeutic value

Current treatment options Leefstijlinterventies, metformine, sulfonylureumderivaten, SGLT2-remmers, GLP-1-receptoragonisten en (zo nodig) dagelijkse insuline.
Therapeutic value No estimate possible yet

This assessment does not indicate any potential inclusion in the package.

Frequency of administration 1 times a week
References NCT05662332 (QWINT-1); NCT05362058 (QWINT-2); NCT05275400 (QWINT-3); NCT05462756 (QWINT-4)

Expected patient volume per year

Patient volume

Market share is generally not included unless otherwise stated.

Expected cost per patient per year

Cost 7,000.00 - 9,000.00

This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

References GIPdatabank
Additional remarks De gemiddelde vergoeding per gebruiker van insulines en analogen ligt tussen de €7.000 en €9.000.

Potential total cost per year

Off label use

Indication extension

Other information